¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inflammatory carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • renal cell carcinoma
    ÄáÆÏ¼¼Æ÷¾ÏÁ¾, ½ÅÀå¼¼Æ÷¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷Á¦ÀÚ¸®¾ÏÁ¾
  • sebaceous carcinoma
    ÇÇÁö»ù¾ÏÁ¾, ±â¸§»ù¾ÏÁ¾
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • urothelial carcinoma
    ¿ä·Î»óÇǼ¼Æ÷¾ÏÁ¾
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • verrucous carcinoma
    »ç¸¶±Í¸ð¾ç¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • tubular carcinoma
    °ü¾ÏÁ¾
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • urothelial carcinoma
    ¿ä·Î»óÇǼ¼Æ÷¾ÏÁ¾
  • verrucous carcinoma
    »ç¸¶±Í¸ð¾ç¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • breast,carcinoma scirrhous
    °æÁú¼º (Ìãòõàõ)
  • brochioloalveolar carcinoma
    ¼¼±â°üÁö ÆóÆ÷¾ÏÁ¾(á¬Ñ¨Î·ò¨øËøàäßðþ)
  • bronchiolar carcinoma
    ¼¼±â°üÁö¼º ¾Ï(Á¾)(¡­àõäßðþ).
  • bronchogenic carcinoma
    ±â°üÁö¿ø¼º ¾ÏÁ¾(¡­äßðþ).
  • bronchogenic carcinoma
    ±â°üÁö¿ø¼º ¾ÏÁ¾(¡­äßðþ)
  • carcinoma
    ¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾ (äßðþ)
  • carcinoma dose
    Á¦¾Ï·®.
  • carcinoma en cuirasse
    °©¿Ê ¾Ï(Á¾)
  • carcinoma erysipelatodes
    ´Üµ¶¾ç¾ÏÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾(ß¾ù«Ò®äßðþ), µ¿¼Ò³»¾ÏÁ¾(ÔÒá¶Ò®äßðþ), ÀνÃÅõ¾ÏÁ¾
  • carcinoma of prostate
    Àü¸³¼±¾Ï
  • carcinoma of thyroid, papillary
    °©»ó¼± À¯µÎ»ó¾ÏÁ¾
  • carcinoma pearl
    ¾ÏÁ¾ÁÖ(¾ÏÁ¾ÁÖ).
  • carcinoma portionis<³ª>
    ÀÚ±ÃÁúºÎ¾ÏÁ¾(í­ÏàòóÝ»äßðþ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
IDP immunodiffusion procedure; inflammatory demyelinating neuropathy; initial dose period; inosine dipho...
IFP inflammatory fibroid polyp; insulin, compound F [hydrocortisone], prolactin; intermediate filament p...
IJD inflammatory joint disease
Inflamm inflammation, inflammatory
IPD idiopathic Parkinson disease; idiopathic protracted diarrhea; immediate pigment darkening; increase ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MIP-1beta Macrophage inflammatory protein-1beta
NSAID Non Steroid Anti-Inflammatory Drugs
NSAID Non Steroidal Anti-Inflammatory Drug
NSAID non steroidal anti-inflammatory agents
NSAI Non-steroidal anti-inflammatory
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • epithelial carcinoma
    »óÇÇ ¾ÏÁ¾
  • fibrosing basal cell carcinoma
    ¼¶À¯¼º ±âÀú ¼¼Æ÷ ¾Ï
  • infiltrating duct breast carcinoma
    ħÀ±¼º °ü»ó À¯¹æ ¾Ï
  • intraductal carcinoma
    ¼±°ü³» ¾Ï
  • invasive carcinoma
    ħ½À¼º ¾ÏÁ¾
  • invasive squamous cell carcinoma
    ħÀÔ¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • inverted nipples breast carcinoma
    ÇÔ¸ô À¯µÎ À¯¹æ ¾Ï
  • laryngeal carcinoma
    ÈĵξÏ
    Èĵο¡ ¹ß»ýÇÏ´Â ¾Ï. 95 % ÀÌ»óÀÌ Á¶Á÷ÇÐÀûÀ¸·Î ÆíÆò »óÇǾÏ
  • latent carcinoma
    ÀáÀ缺 ¾Ï
    ºÐ¸íÈ÷ ¾ÏÀÌÁö¸¸ ÀÓ»óÀûÀ¸·Î Áõ»óÀÌ ¾øÀ¸¸ç, ¿¬·É Áõ°¡ ½Ã ÇÔ²² Áõ°¡ÇÑ´Ù.
  • lobular breast carcinoma in situ
    ¼Ò¿±¼º, ºñħÀ±¼º À¯¹æ ¾Ï
  • medullary carcinoma
    ¼öÁú¼º ¾ÏÁ¾
  • morphealike basal cell carcinoma
    ¹Ý»ó °æÇÇÁõ °°Àº ±âÀú ¼¼Æ÷¾Ï
  • mucinous breast carcinoma
    Á¡¾×¼º À¯¹æ ¾Ï
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • nonseminomatous testicular carcinoma
    ºñÁ¤»ó ÇÇÁ¾¼º °íȯ ¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, hepatocellular Primary carcinoma of the liver cells. It ranges from a well-differentiated tumour difficult to distinguish from normal hepatocytes to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic or may form giant cells. Several classification schemes have been suggested. Hepatocellular carcinoma is very rare in the united states and western europe, but it is one of the most common cancers in eastern asia and sub-saharan africa. The cases are preponderantly male and, racially, whites have the lowest rates.
(12 Dec 1998)
carcinoma, infiltrating duct An invasive (infiltrating) carcinoma of the breast. This carcinoma in which no special histological feature is recognised is designated nos or not otherwise specified and is by far the most common ductal tumour, accounting for almost 70% of breast cancers. It is characterised by stony hardness upon palpation. It commonly metastasizes to the axillary lymph nodes and its prognosis is the poorest of the various ductal types.
(12 Dec 1998)
carcinoma in situ Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
carcinoma, intraductal, noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterised by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Its true incidence is uncertain but all noninvasive breast carcinomas comprise almost 5% of all neoplastic lesions of the female breast, with this carcinoma accounting for about 50% of these, or 2.5%-2.8% of all tumours.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, large cell A tumour of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic.
(12 Dec 1998)
carcinoma, lewis lung A carcinoma discovered by dr. Margaret r. Lewis of the wistar institute in 1951. This tumour originated spontaneously as a carcinoma of the lung of a c57bl mouse. The tumour does not appear to be grossly haemorrhagic and the majority of the tumour tissue is a semifirm homogeneous mass. It is also called 3ll and llc and is used as a transplantable malignancy.
(12 Dec 1998)
carcinoma, lobular A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumours in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces.
(12 Dec 1998)
carcinoma, medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, mucoepidermoid A tumour of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumours of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumour of the parotid.
(12 Dec 1998)
carcinoma myxomatodes An obsolete term for a form of colloid cancer in which there is myxomatous metaplasia of the cellular fibrous stroma.
(05 Mar 2000)
carcinoma, neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumours include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, merkel cell tumour, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumours, and pheochromocytoma. Neurosecretory granules are found within the tumour cells.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á